Cargando…
Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?
Recently, the Food and Drug Administration placed a "black box" label on etanercept, and other tumor necrosis factor inhibitors used to treat childhood arthritis, warning of the risk of malignancies. The Food and Drug Administration made their decision based on a review of 48 cases of mali...
Autores principales: | Cron, Randy Q, Beukelman, Timothy |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931479/ https://www.ncbi.nlm.nih.gov/pubmed/20712883 http://dx.doi.org/10.1186/1546-0096-8-23 |
Ejemplares similares
-
Temporomandibular joint arthritis in patients with non-JIA childhood arthritis
por: Cron, Randy Q, et al.
Publicado: (2012) -
DNase I levels and disease outcome in JIA patients treated with etanercept
por: Lazarević, D, et al.
Publicado: (2011) -
Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study
por: Stoll, Matthew L., et al.
Publicado: (2017) -
High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort
por: Record, Jessica L, et al.
Publicado: (2011) -
The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data
por: Davies, Rebecca, et al.
Publicado: (2020)